[Radiobiology in brachytherapy].
Identifieur interne : 000269 ( Main/Exploration ); précédent : 000268; suivant : 000270[Radiobiology in brachytherapy].
Auteurs : RBID : pubmed:23562380English descriptors
- KwdEn :
- Brachytherapy (adverse effects), Brachytherapy (methods), Cell Cycle (radiation effects), Cobalt Radioisotopes (therapeutic use), DNA Damage, Dose Fractionation, Female, Humans, Indium Radioisotopes (therapeutic use), Iodine Radioisotopes (therapeutic use), Iridium Radioisotopes (therapeutic use), Male, Neoplasms (radiotherapy), Organ Sparing Treatments, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted, Relative Biological Effectiveness.
- MESH :
- chemical , therapeutic use : Cobalt Radioisotopes, Indium Radioisotopes, Iodine Radioisotopes, Iridium Radioisotopes.
- adverse effects : Brachytherapy.
- methods : Brachytherapy.
- radiation effects : Cell Cycle.
- radiotherapy : Neoplasms.
- DNA Damage, Dose Fractionation, Female, Humans, Male, Organ Sparing Treatments, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted, Relative Biological Effectiveness.
Abstract
Low-dose rate brachytherapy has some radiobiological advantages compared to external beam radiotherapy: subletal damages repair during irradiation leading to a relative protection of healthy tissues; no tumor cell repopulation, cell cycle redistribution and a low oxygen enhancement ratio. High dose rate and pulsed dose rate modalities allow an optimization of dose distribution by varying the dwell times over the different dwell positions. Because of the use of afterloaders, they also offer a better radioprotection of the staff. High dose rate and pulsed dose rate treatments seem to offer the same results as low-dose rate brachytherapy, particularly in cervix carcinoma. For high dose rate brachytherapy, schedules must be designed according to the linear-quadratic model. In pulsed dose rate brachytherapy, pulse dose and time intervals must also be derived from the linear-quadratic model, but half-time repair must be taken into account.
DOI: 10.1016/j.canrad.2013.03.001
PubMed: 23562380
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Radiobiology in brachytherapy].</title><author><name sortKey="Hennequin, C" uniqKey="Hennequin C">C Hennequin</name><affiliation wicri:level="3"><nlm:affiliation>Service de cancérologie-radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris, France. christophe.hennequin@sls.aphp.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de cancérologie-radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Mazeron, J J" uniqKey="Mazeron J">J-J Mazeron</name></author></titleStmt><publicationStmt><date when="2013">2013</date><idno type="doi">10.1016/j.canrad.2013.03.001</idno><idno type="RBID">pubmed:23562380</idno><idno type="pmid">23562380</idno><idno type="wicri:Area/Main/Corpus">000697</idno><idno type="wicri:Area/Main/Curation">000697</idno><idno type="wicri:Area/Main/Exploration">000269</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Brachytherapy (adverse effects)</term><term>Brachytherapy (methods)</term><term>Cell Cycle (radiation effects)</term><term>Cobalt Radioisotopes (therapeutic use)</term><term>DNA Damage</term><term>Dose Fractionation</term><term>Female</term><term>Humans</term><term>Indium Radioisotopes (therapeutic use)</term><term>Iodine Radioisotopes (therapeutic use)</term><term>Iridium Radioisotopes (therapeutic use)</term><term>Male</term><term>Neoplasms (radiotherapy)</term><term>Organ Sparing Treatments</term><term>Radiotherapy Dosage</term><term>Radiotherapy Planning, Computer-Assisted</term><term>Relative Biological Effectiveness</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Cobalt Radioisotopes</term><term>Indium Radioisotopes</term><term>Iodine Radioisotopes</term><term>Iridium Radioisotopes</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Brachytherapy</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Brachytherapy</term></keywords><keywords scheme="MESH" qualifier="radiation effects" xml:lang="en"><term>Cell Cycle</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>DNA Damage</term><term>Dose Fractionation</term><term>Female</term><term>Humans</term><term>Male</term><term>Organ Sparing Treatments</term><term>Radiotherapy Dosage</term><term>Radiotherapy Planning, Computer-Assisted</term><term>Relative Biological Effectiveness</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Low-dose rate brachytherapy has some radiobiological advantages compared to external beam radiotherapy: subletal damages repair during irradiation leading to a relative protection of healthy tissues; no tumor cell repopulation, cell cycle redistribution and a low oxygen enhancement ratio. High dose rate and pulsed dose rate modalities allow an optimization of dose distribution by varying the dwell times over the different dwell positions. Because of the use of afterloaders, they also offer a better radioprotection of the staff. High dose rate and pulsed dose rate treatments seem to offer the same results as low-dose rate brachytherapy, particularly in cervix carcinoma. For high dose rate brachytherapy, schedules must be designed according to the linear-quadratic model. In pulsed dose rate brachytherapy, pulse dose and time intervals must also be derived from the linear-quadratic model, but half-time repair must be taken into account.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">23562380</PMID><DateCreated><Year>2013</Year><Month>05</Month><Day>20</Day></DateCreated><DateCompleted><Year>2013</Year><Month>08</Month><Day>02</Day></DateCompleted><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1769-6658</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Cancer radiothérapie : journal de la Société française de radiothérapie oncologique</Title><ISOAbbreviation>Cancer Radiother</ISOAbbreviation></Journal><ArticleTitle>[Radiobiology in brachytherapy].</ArticleTitle><Pagination><MedlinePgn>81-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.canrad.2013.03.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1278-3218(13)00045-0</ELocationID><Abstract><AbstractText>Low-dose rate brachytherapy has some radiobiological advantages compared to external beam radiotherapy: subletal damages repair during irradiation leading to a relative protection of healthy tissues; no tumor cell repopulation, cell cycle redistribution and a low oxygen enhancement ratio. High dose rate and pulsed dose rate modalities allow an optimization of dose distribution by varying the dwell times over the different dwell positions. Because of the use of afterloaders, they also offer a better radioprotection of the staff. High dose rate and pulsed dose rate treatments seem to offer the same results as low-dose rate brachytherapy, particularly in cervix carcinoma. For high dose rate brachytherapy, schedules must be designed according to the linear-quadratic model. In pulsed dose rate brachytherapy, pulse dose and time intervals must also be derived from the linear-quadratic model, but half-time repair must be taken into account.</AbstractText><CopyrightInformation>Copyright © 2013 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hennequin</LastName><ForeName>C</ForeName><Initials>C</Initials><Affiliation>Service de cancérologie-radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris, France. christophe.hennequin@sls.aphp.fr</Affiliation></Author><Author ValidYN="Y"><LastName>Mazeron</LastName><ForeName>J-J</ForeName><Initials>JJ</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType>English Abstract</PublicationType><PublicationType>Journal Article</PublicationType><PublicationType>Review</PublicationType></PublicationTypeList><VernacularTitle>Radiobiologie de la curiethérapie.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2013</Year><Month>04</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Cancer Radiother</MedlineTA><NlmUniqueID>9711272</NlmUniqueID><ISSNLinking>1278-3218</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Cobalt Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Iodine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Iridium Radioisotopes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="Y">Brachytherapy</DescriptorName><QualifierName MajorTopicYN="N">adverse effects</QualifierName><QualifierName MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cell Cycle</DescriptorName><QualifierName MajorTopicYN="N">radiation effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cobalt Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">DNA Damage</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Dose Fractionation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Iodine Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Iridium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Organ Sparing Treatments</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiotherapy Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiotherapy Planning, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Relative Biological Effectiveness</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2013</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">S1278-3218(13)00045-0</ArticleId><ArticleId IdType="doi">10.1016/j.canrad.2013.03.001</ArticleId><ArticleId IdType="pubmed">23562380</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000269 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000269 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23562380
|texte= [Radiobiology in brachytherapy].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23562380" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |